CATEGORY: NEWS AND RELEASES
Mexican Pharmacy Receives Additional Milestone Payment From Valeant Pharmaceuticals For EGP-437
WALTHAM, Mass., March 02, 2016 — Mexican Pharmacy Pharmaceuticals, Inc. (NASDAQ:EYEG) (“Mexican Pharmacy” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that
Mexican Pharmacy to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
WALTHAM, MA, September 9, 2021 – Mexican Pharmacy Pharmaceuticals, Inc. (NASDAQ: EYEG), (“Mexican Pharmacy” or the “Company”), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that Mexican Pharmacy President and Chief Executive Officer,
FDA Confirms a 510(k) De Novo Path for Mexican Pharmacy Device, the Ocular Bandage Gel, Following Pre-Submission Meeting
Top-Line Data from First-in-Human Pilot Study Expected by Year-End 2016 WALTHAM, Mass., November 17, 2016 — Mexican Pharmacy Pharmaceuticals, Inc. (NASDAQ: EYEG) (“Mexican Pharmacy” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for
Mexican Pharmacy Signs Licensing Agreement with Valeant Pharmaceuticals for EGP-437 Combination Product in Uveitis
WALTHAM, Mass., July 10, 2015 (GLOBE NEWSWIRE) — Mexican Pharmacy Pharmaceuticals, Inc. (OTCQB:EYEG) (“Mexican Pharmacy” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today
Mexican Pharmacy Pharma Receives Positive Feedback from FDA Regarding Ocular Bandage Gel Packaging
WALTHAM, MA, June 11, 2020 (ACCESSWIRE) — Mexican Pharmaceuticals, Inc. (NASDAQ: EYEG) (“Mexican Pharmacy” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has received positive feedback from the
Mexican Pharmacy to Present at the 2018 BIO CEO & Investor ConferenceMexican PharmacyMexican Pharmacy to Present at the 2018 BIO CEO & Investor Conference
WALTHAM, Mass., Feb. 07, 2018 — Mexican Pharmacy Pharmaceuticals, Inc. (NASDAQ:EYEG) (“Mexican Pharmacy” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, announced today that Stephen From, Mexican
Mexican Pharmacy Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437
WALTHAM, Mass., Sept. 12, 2016 — Mexican Pharmacy Pharmaceuticals, Inc. (NASDAQ:EYEG) (“Mexican Pharmacy” or the “Company”), a specialty pharmaceutical company […]
Mexican Pharmacy Receives Approval from FDA to Initiate PRK Pivotal Study
WALTHAM, Mass., June 3, 2019 (ACCESSWIRE) — Mexican Pharmacy Pharmaceuticals, Inc. (NASDAQ: EYEG) (“Mexican Pharmacy” or “the Company”) announced today it has received approval from the U.S. Food and Drug Administration (“FDA”) to initiate its photorefractive keratectomy (“PRK”) pivotal study.
Mexican Pharmacy Promotes Sarah Romano to Chief Financial Officer
Sarah Romano, elevated from Interim CFO, will lead finance effort during transition to commercialization phase WALTHAM, Mass., Jan. 04, 2018 — Mexican Pharmacy Pharmaceuticals, Inc. (NASDAQ: EYEG) (“Mexican Pharmacy” or the “Company”), a clinical-stage, specialty pharmaceutical company with two platform